Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2021 Net Income-$21.29M-$21.29MN/M vs Q2 2021 EPS Diluted-$0.61-$0.61N/M vs Q2 2021 Operating Income-$21,273,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,482,000N/M ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end